



# *PathXL Simulator*

*Dr. James Diamond  
PathXL*


- Developed by pathologists
- Standardising Training
- Virtual Learning Environment
- Consequence Free Environment
- Multi-modal Environment



- There is a desire overcome some of the fundamental limitations of one-on-one training.
- It is into this arena that ***diagnostic simulation*** is making an impact with the introduction of PathXL Simulator.
- The role of the simulator in this modality is to mimic the real world diagnostic environment.
- Trainees can explore it, interact and understand it before the techniques can be applied in the real world.
- Consequence Free Learning Environment



	None	Mild	Moderate	Severe
<b>Normal</b>	0.95	0.05	0.04	0.01
<b>Koilocytosis</b>	0.20	0.70	0.08	0.02
<b>CIN 1</b>	0.01	0.80	0.15	0.04
<b>CIN 2</b>	0.01	0.20	0.50	0.29
<b>CIN 3</b>	0.01	0.10	0.29	0.60




Diagnosis / Grading



Normal	0.00
Koilocytosis	0.00
CIN 1	0.00
CIN 2	0.11
<b>CIN 3</b>	<b>0.88</b>

Diagnosis / Grading






### Nuclear Pleomorphism

None

Mild

Moderate

Severe






None

Mild

Moderate

Severe





## PathXL Simulator

- Deconstruct diagnosis into key components
- Defined series of Diagnostic Clues (*& Grades*)
- Decision analysis based on image comparison
- Objective tracking of the decision process
- Objective assessment of performance (*& Feedback*)
- Comparison with experienced pathologist
- Multi-media training


# Launch Demonstration

## Professor Christopher Womack


- Principal Clinical Histopathologist,  
Oncology Translational Science
- Acting Global Biobank Head
- Honorary Professor School of  
Cancer and Enabling sciences,  
University of Manchester, UK



## AZ 3-tier oncology target-disease linkage TMA strategy




Target Expression




Disease Area Linkage

Disease Segments  
(prioritised)




Target Expression



Disease Area  
Linkage


Disease Segments  
(prioritised)



## More pathologists



## Image Analysis



**Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells are associated with colorectal metastatic tumour progression**

H.K. Angell<sup>1</sup>, X. Huan<sup>2</sup>, S. Mistry<sup>2</sup>, M. Cumberbatch<sup>2</sup>, N. Gray<sup>2</sup>, C. Womack<sup>2</sup>, S.A. Watson<sup>3</sup>, D.I. Pritchard<sup>1</sup>, R.W. Wilkinson<sup>4</sup>

NCRI 2011

**Quantitative assessment of tumour infiltrating lymphocytes using Genie™ pattern recognition software for the separate analysis of tumour versus stroma in head and neck squamous cell carcinoma (HNSCC) improves biomarker reproducibility**

X. H. Yap<sup>1</sup>, H. K. Angell<sup>2</sup>, N. Gray<sup>1</sup>, C. Womack<sup>1</sup>, R. W. Wilkinson<sup>1</sup>, M. Cumberbatch<sup>1</sup>

## Trained Scientists

1. Intro modules
2. Simulator
3. Microscope Sessions
4. Competency Assessment

**Pathology Teaching - Breast**

**Purpose**

- This is an introduction prior to separate e-based self learning and self assessment.
- Following the self-assessment you will be confident that you can
  - Recognise tissue originating from the breast
  - Distinguish neoplastic from non-neoplastic tissue
  - Identify breast carcinoma
  - Grade breast cancer
- ... so that you are able to primary read human tissue slides and digital images.
- Competency will be assessed by a medically trained pathologist prior to sign-off and annual review.

Breast Cancer Disease Area

AstraZeneca  
RESEARCH & DEVELOPMENT  
CANCER & INFECTION

- Fits in to a learning package of self teaching and training for non medical scientists in oncology drug development
- Specifically, provides logical, structured, pathologist-developed morphological approach that mimics real diagnosis
- Supplements but does not replace pathologist 1:1 training and continuous assessment
- Facilitates high throughput immunohistochemistry and image analysis for biomarker-disease linkage:
  - Improves efficiency
  - Reduces timelines

*Thank You*

*Any Questions?*

*digital workflow excellence*